Filtered By:
Specialty: Hematology
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 2753 results found since Jan 2013.
Optimal anti-platelet therapy for older patients with acute coronary syndrome: a network meta-analysis of randomized trials comprising 59,284 older patients
AbstractThe aim of this study was to identify the optimal anti-platelet therapy in older acute coronary syndrome (ACS) patients with a mean age ≥ 60 years by comparing the efficacy and safety of different anti-platelet therapies. The selection of antiplatelet therapy in older patients with ACS is a clinical challenge. Numerous evidences indicate that the de-escalation of dual anti-platelet therapy (DAPT) or P2Y12 inhibitor monotherap y may reduce bleeding risk without increasing thrombotic events. However, there is a lack of systematic reviews and optimal strategy analysis regarding older ACS patients. Randomized co...
Source: Journal of Thrombosis and Thrombolysis - August 7, 2023 Category: Hematology Source Type: research
Outcomes in infants with unprovoked venous thromboembolism: A retrospective cohort study
CONCLUSION: There is a low rate of recurrent VTE but significant end-organ morbidity in infants with unprovoked VTE.PMID:37538506 | PMC:PMC10394551 | DOI:10.1016/j.rpth.2023.100174
Source: Thrombosis and Haemostasis - August 4, 2023 Category: Hematology Authors: Hilary Whitworth Lauren A Beslow Rebecca A Hubbard Charles E Leonard Rebecca Scobell Char Witmer Leslie Raffini Source Type: research
Thrombus composition and thrombolysis resistance in stroke
Res Pract Thromb Haemost. 2023 May 16;7(4):100178. doi: 10.1016/j.rpth.2023.100178. eCollection 2023 May.ABSTRACTA State of the Art lecture titled "Thrombus Composition and Thrombolysis Resistance in Stroke" was presented at the ISTH Congress in 2022. Intravenous thrombolysis (IVT) remains the only pharmacologic option to re-establish cerebral perfusion at the acute phase of ischemic stroke. IVT is based on the administration of recombinant tissue plasminogen activator with the objective of dissolving fibrin, the major fibrillar protein component of thrombi. Almost 30 years on from its introduction, although the clinical b...
Source: Thrombosis and Haemostasis - August 4, 2023 Category: Hematology Authors: Benoit Ho-Tin-No é Jean-Philippe Desilles Mikael Mazighi Source Type: research
Outcomes in infants with unprovoked venous thromboembolism: A retrospective cohort study
CONCLUSION: There is a low rate of recurrent VTE but significant end-organ morbidity in infants with unprovoked VTE.PMID:37538506 | PMC:PMC10394551 | DOI:10.1016/j.rpth.2023.100174
Source: Thrombosis and Haemostasis - August 4, 2023 Category: Hematology Authors: Hilary Whitworth Lauren A Beslow Rebecca A Hubbard Charles E Leonard Rebecca Scobell Char Witmer Leslie Raffini Source Type: research
Thrombus composition and thrombolysis resistance in stroke
Res Pract Thromb Haemost. 2023 May 16;7(4):100178. doi: 10.1016/j.rpth.2023.100178. eCollection 2023 May.ABSTRACTA State of the Art lecture titled "Thrombus Composition and Thrombolysis Resistance in Stroke" was presented at the ISTH Congress in 2022. Intravenous thrombolysis (IVT) remains the only pharmacologic option to re-establish cerebral perfusion at the acute phase of ischemic stroke. IVT is based on the administration of recombinant tissue plasminogen activator with the objective of dissolving fibrin, the major fibrillar protein component of thrombi. Almost 30 years on from its introduction, although the clinical b...
Source: Thrombosis and Haemostasis - August 4, 2023 Category: Hematology Authors: Benoit Ho-Tin-No é Jean-Philippe Desilles Mikael Mazighi Source Type: research
Outcomes in infants with unprovoked venous thromboembolism: A retrospective cohort study
CONCLUSION: There is a low rate of recurrent VTE but significant end-organ morbidity in infants with unprovoked VTE.PMID:37538506 | PMC:PMC10394551 | DOI:10.1016/j.rpth.2023.100174
Source: Thrombosis and Haemostasis - August 4, 2023 Category: Hematology Authors: Hilary Whitworth Lauren A Beslow Rebecca A Hubbard Charles E Leonard Rebecca Scobell Char Witmer Leslie Raffini Source Type: research
Thrombus composition and thrombolysis resistance in stroke
Res Pract Thromb Haemost. 2023 May 16;7(4):100178. doi: 10.1016/j.rpth.2023.100178. eCollection 2023 May.ABSTRACTA State of the Art lecture titled "Thrombus Composition and Thrombolysis Resistance in Stroke" was presented at the ISTH Congress in 2022. Intravenous thrombolysis (IVT) remains the only pharmacologic option to re-establish cerebral perfusion at the acute phase of ischemic stroke. IVT is based on the administration of recombinant tissue plasminogen activator with the objective of dissolving fibrin, the major fibrillar protein component of thrombi. Almost 30 years on from its introduction, although the clinical b...
Source: Thrombosis and Haemostasis - August 4, 2023 Category: Hematology Authors: Benoit Ho-Tin-No é Jean-Philippe Desilles Mikael Mazighi Source Type: research
Geographic variation in clinical outcomes and anticoagulation among medicare beneficiaries with non-valvular atrial fibrillation
AbstractOral anticoagulants (OACs) have been used to prevent stroke/systemic embolism (SE) among patients with non-valvular atrial fibrillation (NVAF). To evaluate baseline clinical characteristics, incidence rates of stroke/SE and hospitalization for bleeding, and OAC use among elderly patients with NVAF in the US by geographic region. Patients with NVAF were selected from the US Centers for Medicare& Medicaid Services claims database (01JAN2013-31DEC2016). Twelve months of health plan enrollment was required before and after the NVAF diagnosis to evaluate baseline characteristics and outcomes, respectively. Each pati...
Source: Journal of Thrombosis and Thrombolysis - August 2, 2023 Category: Hematology Source Type: research
Temporal trends in anticoagulation use and clinical outcomes among medicare beneficiaries with non-valvular atrial fibrillation
ConclusionsThe proportions of patients with non-valvular atrial fibrillation who were not prescribed an oral anticoagulant decreased but remained high. We observed an increase in direct oral anticoagulant use that coincided with decreased incidence of clinical outcomes as well as decreasing total healthcare costs.
Source: Journal of Thrombosis and Thrombolysis - August 2, 2023 Category: Hematology Source Type: research
Real world time trends in antithrombotic treatment for newly diagnosed atrial fibrillation in China: reports from the GLORIA-AF Phase III registry
Stroke prevention with oral anticoagulant (OAC) therapy, including non-vitamin K antagonist oral anticoagulants (NOACs), is recommended in patients with atrial fibrillation (AF). This analysis describes the an...
Source: Thrombosis Journal - August 1, 2023 Category: Hematology Authors: Xiaoxia Liu, Guoze Feng, Sabrina Vogel Marler, Menno V Huisman, Gregory Y. H. Lip and Changsheng Ma Tags: Research Source Type: research
D-dimer to fibrinogen ratio predicts early neurological deterioration in ischemic stroke with atrial fibrillation
The D-dimer to fibrinogen ratio (DFR) is a good indicator of clot-producing activity in thrombotic disease, but its clinical usefulness in stroke patients with nonvalvular atrial fibrillation (NVAF) has not been studied. We evaluated the association between the DFR and early neurological deterioration (END) in acute ischemic stroke (AIS) patients with NVAF.
Source: Thrombosis Research - July 31, 2023 Category: Hematology Authors: Ki-Woong Nam, Chi Kyung Kim, Sungwook Yu, Kyungmi Oh, Jong-Won Chung, Oh. Young Bang, Gyeong-Moon Kim, Jin-Man Jung, Tae-Jin Song, Yong-Jae Kim, Bum Joon Kim, Sung Hyuk Heo, Kwang-Yeol Park, Jeong-Min Kim, Jong-Ho Park, Jay Chol Choi, Man-Seok Park, Joon- Tags: Full Length Article Source Type: research
Comparison of early and delayed anticoagulation therapy after ischemic stroke in patients with atrial fibrillation: a systematic review and meta-analysis
AbstractThe optimal initiation timing of oral anticoagulants (OACs) remains controversial in patients with atrial fibrillation (AF)-related acute ischemic stroke (AIS). The aim of this study is to compare the efficacy and safety of early OACs initiation with that of the delayed initiation for AIS and AF.We searched systematically the following mainstream databases: PubMed, Embase, and Web of Science from the inception to July 2023 for studies that compared the early initiation with the delayed initiation of OACs for AF-related AIS patients. Outcome measures were the incidence of hemorrhagic events, ischemic events, and com...
Source: Journal of Thrombosis and Thrombolysis - July 28, 2023 Category: Hematology Source Type: research
Ischemic Stroke in Cancer: Mechanisms, Biomarkers, and Implications for Treatment
Semin Thromb Hemost DOI: 10.1055/s-0043-1771270Ischemic stroke is an important cause of morbidity and mortality in cancer patients. The underlying mechanisms linking cancer and stroke are not completely understood. Long-standing and more recent evidence suggests that cancer-associated prothrombotic states, along with treatment-related vascular toxicity, such as with chemotherapy and immunotherapy, contribute to an increased risk of ischemic stroke in cancer patients. Novel biomarkers, including coagulation, platelet and endothelial markers, cell-free DNA, and extracellular vesicles are being investigated for their potentia...
Source: Seminars in Thrombosis and Hemostasis - July 28, 2023 Category: Hematology Authors: Costamagna, Gianluca Navi, Babak B. Beyeler, Morin Hottinger, Andreas F. Alberio, Lorenzo Michel, Patrik Tags: Review Article Source Type: research
Aspirin and clopidogrel resistance; a neglected gap in stroke and cardiovascular practice in Iran: a systematic review and meta-analysis
Antiplatelet drugs, such as Aspirin and Clopidogrel (Plavix) are effective in the primary prevention of thromboembolic events. They are commonly used to reduce the risk of recurrence of thromboembolism. The bo...
Source: Thrombosis Journal - July 27, 2023 Category: Hematology Authors: Mohammad Parsa-kondelaji and Hassan Mansouritorghabeh Tags: Review Source Type: research
Hyperhomocysteinemia potentiates megakaryocyte differentiation and thrombopoiesis via GH-PI3K-Akt axis
Hyperhomocysteinemia (HHcy) is closely associated with thrombotic diseases such as myocardial infarction and stroke. Enhanced platelet activation was observed in animals and humans with HHcy. However, the infl...
Source: Journal of Hematology and Oncology - July 27, 2023 Category: Hematology Authors: Wenjing Lei, Zhuoliang Liu, Zhiyuan Su, Panpan Meng, Chun Zhou, Xiaomei Chen, Zheng Hu, An Xiao, Miaomiao Zhou, Liping Huang, Yiyue Zhang, Xianhui Qin, Junping Wang, Fengxin Zhu and Jing Nie Tags: Correspondence Source Type: research
